title: Circulating 25-hydroxyvitamin D3 and survival after diagnosis with kidney cancer.
abstract: Prospective cohort studies have provided some evidence that circulating vitamin D is associated with risk of, and survival from, renal cell carcinoma (RCC), but it is unclear whether concentrations of vitamin D at the time of diagnosis of RCC are associated with prognosis. We conducted a case-cohort study of 630 RCC cases, including 203 deaths, from a multicenter case-control study in Eastern Europe. Vitamin D was assessed as 25-hydroxyvitamin D3 [25(OH)D3], and we used weighted Cox models to estimate hazard ratios (HR) and 95% confidence intervals (CI) by categories of season-adjusted 25(OH)D3. Higher concentrations of 25(OH)D3 were associated with lower risk of death after adjusting for stage, age, sex, and country (HR highest vs. lowest category 0.57; 95% CI, 0.34-0.97). The inverse associations of 25(OH)D3 with death were most notable among those who died from non-RCC causes and those diagnosed with early-stage disease. In summary, 25(OH)D3 concentration at diagnosis of RCC was inversely associated with all-cause mortality rates, but not specifically with RCC outcome.
authors.affiliation: International Agency for Research on Cancer (IARC), Lyon, France. JohanssonM@iarc.fr MullerD@fellows.iarc.fr.
authors.forename: David C
authors.initials: DC
authors.lastname: Muller
authors.affiliation: International Agency for Research on Cancer (IARC), Lyon, France.
authors.forename: Ghislaine
authors.initials: G
authors.lastname: Scelo
authors.affiliation: Russian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
authors.forename: David
authors.initials: D
authors.lastname: Zaridze
authors.affiliation: Department of Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Janout
authors.affiliation: Charles University in Prague, First Faculty of Medicine, Institute of Hygiene and Epidemiology, Prague, Czech Republic.
authors.forename: Ivana
authors.initials: I
authors.lastname: Holcatova
authors.affiliation: Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Marie
authors.initials: M
authors.lastname: Navratilova
authors.affiliation: National Institute of Public Health, Bucharest, Romania.
authors.forename: Dana
authors.initials: D
authors.lastname: Mates
authors.affiliation: Bevital AS, Bergen, Norway.
authors.forename: Øivind
authors.initials: Ø
authors.lastname: Midttun
authors.affiliation: Department of Clinical Science, University of Bergen, Bergen, Norway. Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway.
authors.forename: Per Magne
authors.initials: PM
authors.lastname: Ueland
authors.affiliation: International Agency for Research on Cancer (IARC), Lyon, France.
authors.forename: Paul
authors.initials: P
authors.lastname: Brennan
authors.affiliation: International Agency for Research on Cancer (IARC), Lyon, France. JohanssonM@iarc.fr MullerD@fellows.iarc.fr.
authors.forename: Mattias
authors.initials: M
authors.lastname: Johansson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis; D014807:Vitamin D / Q000378:metabolism*
chemical_list: D014807:Vitamin D